IRWD — IRONWOOD PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1446847 ·
Last close
$4.23
Market Cap
$696.31M
52W High
$4.88
52W Low
$3.15
ADV30
2,429,213
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 106,506,000 | — | 72,533,000 | 40,773,000 | 434,566,000 | 220,471,000 | 651,710,000 |
| Dec 2025 | 47,709,000 | — | 6,553,000 | -2,276,000 | 396,901,000 | 215,456,000 | 658,736,000 |
| Sep 2025 | 122,060,000 | — | 77,684,000 | 40,080,000 | 396,062,000 | 140,407,000 | 660,219,000 |
| Jun 2025 | 85,239,000 | — | 45,071,000 | 23,599,000 | 342,946,000 | 92,852,000 | 651,108,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,044,000
Investing CF
$-34,000
Financing CF
$216,000
CapEx
$-51,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.13
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,673,718,000
Inventory
—
Receivables
$46,745,000
ST Investments
—
EBIT TTM
$102,600,000
Pretax Income TTM
$70,025,000
Interest Exp TTM
$32,575,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$361,513,984
EBITDA
$203,879,008
Free Cash Flow
$51,157,624
Enterprise Value
$1,073,199,680
Total Cash
$220,471,008
Total Debt
$597,356,032
Shares Out
164,613,406
Trailing EPS
$0.62
Book Value
$-1.32
ROE
—
ROA
33.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 296,151,000 | 118,759,000 | 24,017,000 | 396,901,000 | 658,736,000 | — | 127,044,000 |
| Dec 2024 | 351,410,000 | 95,717,000 | 880,000 | 350,908,000 | 652,243,000 | — | 103,549,000 |
| Dec 2023 | 442,735,000 | 168,336,000 | -1,002,239,000 | 471,073,000 | 817,368,000 | — | 183,427,000 |
| Dec 2022 | 410,596,000 | 250,337,000 | 175,065,000 | 1,100,519,000 | 448,141,000 | — | 273,763,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.44
Max Pain — expiry 2026-08-21
max pain strike: $4.00 · spot: $4.23 · call oi: 5,253 · put oi: 4,101
Expected Move to 2026-08-21:
±$0.72
(17.14%) —
implied range
$3.51 –
$4.96
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | $707.88M | $8.75 | — |
| OCS | Oculis Holding AG | $682.99M | $11.31 | — |
| CLYM | Climb Bio, Inc. | $681.43M | $11.90 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $681.06M | $36.81 | — |
| PHAR | Pharming Group N.V. | $713.44M | $10.08 | — |
News headlines (Yahoo Finance, 1h cache)
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
2026-07-30 20:05 · Yahoo
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
2026-07-14 11:30 · Yahoo
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
2026-07-08 14:14 · Yahoo
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
2026-07-08 12:25 · Yahoo
Ironwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings Momentum
2026-07-03 13:12 · Yahoo
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
2026-06-26 08:59 · Yahoo
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
2026-06-25 12:40 · Yahoo
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
2026-06-11 13:38 · Yahoo
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?
2026-06-02 13:58 · Yahoo
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?
2026-05-20 20:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.